ECSP992981A - STABILIZED COMPOSITIONS - Google Patents
STABILIZED COMPOSITIONSInfo
- Publication number
- ECSP992981A ECSP992981A ECSP992981A ECSP992981A EC SP992981 A ECSP992981 A EC SP992981A EC SP992981 A ECSP992981 A EC SP992981A EC SP992981 A ECSP992981 A EC SP992981A
- Authority
- EC
- Ecuador
- Prior art keywords
- magnesium oxide
- ace inhibitor
- compositions
- stabilized compositions
- stabilized
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000005541 ACE inhibitor Substances 0.000 abstract 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 3
- 239000000395 magnesium oxide Substances 0.000 abstract 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 3
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 abstract 1
- 229960001455 quinapril Drugs 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Composiciones que contienen inhibidor de ACE estabilizadas mediante la presencia de óxido de magnesio. Preferentemente, el inhibidor de ACE, quinapril, es protegido de ciertas formas de degradación cuando se prepara en una composición farmacéutica compuesta esencialmente por óxido de magnesio como el agente estabilizador. La presencia de óxido de magnesio también se presta para condiciones de procesamiento favorables durante la fabricación de las composiciones que contienen inhibidor de ACE, especialmente procesamiento mediante granulación en medio húmedo.Compositions containing ACE inhibitor stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor-containing compositions, especially processing by wet granulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP992981 ECSP992981A (en) | 1999-06-04 | 1999-06-04 | STABILIZED COMPOSITIONS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP992981 ECSP992981A (en) | 1999-06-04 | 1999-06-04 | STABILIZED COMPOSITIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP992981A true ECSP992981A (en) | 1999-09-09 |
Family
ID=42043970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP992981 ECSP992981A (en) | 1999-06-04 | 1999-06-04 | STABILIZED COMPOSITIONS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP992981A (en) |
-
1999
- 1999-06-04 EC ECSP992981 patent/ECSP992981A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25546A1 (en) | STABILIZED PHARMACEUTICAL COMPOSITION INCLUDING QUINAPRIL, MAGNESIUM OXIDE AND SACCHARIDE, AND PROCESS FOR ITS PREPARATION. | |
| MA32502B1 (en) | MACROCYCLIC QUINOXALINE COMPOUNDS AS HEPATITIS C VIRUS (HCV) NS3 PROTEASE INHIBITORS | |
| HK1247823A1 (en) | Treatment of osteoporosis | |
| UY27320A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS | |
| BR0014869A (en) | Composition and method for stabilizing it | |
| CL2008000959A1 (en) | Compounds derived from 1,2,4-thiadiazine or 1,4-thiazine; pharmaceutical compositions containing them; and its use for the prevention and / or treatment of infections caused by the hepatitis c virus. | |
| CO5440227A1 (en) | ANTIHELMITIC AND INJECTABLE COMPOSITION IMPROVED GROWTH | |
| WO2004017998A3 (en) | Topical emulsion- gel composition comprising diclofenac sodium | |
| BR0011860A (en) | Antibacterial compositions and process for reducing a population of bacteria on a surface | |
| BRPI0516077A (en) | antimicrobial compositions comprising a natural agent selected from gallic acid, eucalipotol, naringin, a jasminic acid compound and any combination thereof | |
| DK1901755T3 (en) | New pharmaceutical compositions containing hyaluronic acid or its derivatives and collagenase for topical treatment of wounds, burns and ulcers | |
| DE60225143D1 (en) | SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PROPHYLAXIS OF DIABETES | |
| AR047279A1 (en) | LIQUID DETERGENT COMPOSITION | |
| ECSP045110A (en) | COMPOSITIONS OF THE PREPARATION CONTAINING A PHYSIOLOGICALLY ACTIVE COMPOSITE OF UNSTABLE ACIDS AND PROCESSES FOR THEIR PRODUCTION | |
| AR063748A1 (en) | FORMULATION | |
| MXPA03010766A (en) | Novel compounds and compositions as cathepsin inhibitors. | |
| BRPI0408299A (en) | cathepsin inhibitors s | |
| EE05124B1 (en) | The use of docetaxel as an active ingredient or a composition comprising this h drate | |
| DK1414467T3 (en) | Topical treatment of mastalgia | |
| AR039664A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDED BY A LIPASE AND GLUCOMANAN INHIBITOR | |
| AR014983A1 (en) | BIOCID COMPOSITIONS STABLE TO THE SOLAR LIGHT ULTRAVIOLET REGION AND USES OF THE SAME IN THE WATER TREATMENT | |
| BR0213690A (en) | Food Washing Composition | |
| GT200100218A (en) | AGROCHEMICAL COMPOUND | |
| ECSP066685A (en) | COMPOSITION THAT INCLUDES A WATER EXTRACT OF RED VINE LEAVES AND AN AGENT THAT IMPROVES THE BLOOD CIRCULATION FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCIES | |
| MXPA06012566A (en) | Treatment of infectious diseases. |